Validity of c-reactive protein and procalcitonin in the prediction of bacterial infection in patients with liver cirrhosis

BackgroundBreakthrough events are not rare after emerging of Delta variant. On the other hand, long COVID is an unsolved issue where sufferers suffer a lot. Some study has shown that COVID-19 vaccine has improved some clinical and libratory parameters in long COVID. But what will be the possible measures against long COVID after the breakthrough event is still a burning question.MethodWe have observed the third dose by BNT162b2 in a small group(n=20) who were diagnosed as long COVID after breakthrough infections, in Sheikh Hasina National Institute of Burn & Plastic Surgery Institute, Dhaka, Bangladesh. CRP(C-reactive protein) and Anti S1 RBD IgG responses were measured.ResultAll 20 participants in the study received both dosage of “ChAdOx1-nCoV-19” in between February 2021 to April 2021 and had breakthrough infection in the same or following month which led to long COVID syndrome. They all received a third dose of “BNT162b2”. A before and after 3rd dose (14 days after) CRP from participants serum was measured. A Wilcoxon matched paired signed rank test revealed significant (P value <0.05) reduction of inflammatory marker (CRP) after receiving the 3rd vaccine dose. Pre and post 3rd dose quantitative anti S1-RBD IgG response was measured and compared that revealed significant boosting effect that clearly correlates with the CRP response.ConclusionCoverage of vaccines all over the world is still not expected level to control this pandemic. WHO has not recommended the use of a third/booster dose of COVID vaccines. Though our results show some sort of hope for the long COVID in breakthrough events after getting the third dose more study is needed to conclude this issue.

show abstract

C-Reactive Protein as a Prognostic Indicator in COVID-19 Patients

Sadeghi–Haddad–Zavareh

Bayani

Shokri

et al. 2021

Interdisciplinary Perspectives on Infectious Diseases

View full text Add to dashboard Cite

While some biomolecules have been explored to identify potential biomarkers for the prognosis of COVID-19 patients, there is no reliable prognostic indicator of the disease progression and severity. We aimed to evaluate the ability of the C-reactive protein (CRP) to predict COVID-19 infection outcome. This retrospective study was conducted on 429 patients diagnosed with COVID-19 between March 30, 2020, and April 30, 2020. The study population was divided into severe (n = 175) and nonsevere cases (n = 254). Data on demographic characteristics, clinical features, and laboratory findings on admission were collected. The proportion of patients with increased CRP levels was significantly higher in severe cases than in nonsevere patients. Analysis of the receiver operating characteristic (ROC) curve found that CRP could be used as an independent factor in predicting the severity of COVID-19. Also, patients with CRP >64.75 mg/L were more likely to have severe complications. In conclusion, CRP serum levels can predict the severity and progression of illness in patients with COVID-19.

show abstract

Validity of c-reactive protein and procalcitonin in the prediction of bacterial infection in patients with liver cirrhosis

Abstract: Kamal et al., 124Validity of c-reactive protein and procalcitonin in prediction of bacterial infection in patients with liver cirrhosis

Cited by 4 publications

References 8 publications

RETRACTED ARTICLE: Evaluation of ferritin level in COVID-19 patients and its inflammatory response

RETRACTED ARTICLE: Evaluation of ferritin level in COVID-19 patients and its inflammatory response

Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infections

C-Reactive Protein as a Prognostic Indicator in COVID-19 Patients

Contact Info

Product

Resources

About